Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Good write up on Mode for new investors
https://spongeshare.com/research/mode-global-plc-research-note
Have been invested since last year and it's clear that the market is waiting for confirmation of actual revenue and to prove that the business model does work before the SP rerates. Hopefully we will gain some traction in H2 of this year.
This is similar to another fintech company - Mode where the SP has not moved really since IPO until it can prove that it's business model works with their open banking payments platform and confirmation that they can sign up some of the big merchants like supermarkets.
Both companies have huge potential in terms of a really scalable business model whilst disrupting the financial world.
Don't forget the CEO has a decent chunk of the company with 6.6% of the total shares so he will be incentivized to bring value for shareholders. 2021 H2 should have lots of news flow for all the portfolio companies.
For new investors - worth checking out the below links to learn about Guident
https://guident.co/wp-content/uploads/2020/11/Guident-Investor-Presentation-20201102a.pdf
https://www.youtube.com/watch?v=smHNzBChUJ8
Guident owns or holds the exclusive licence to a group of patents that we believe can improve the safety of autonomous vehicles and land-based autonomous delivery devices once brought to market. Guident has significantly progressed it R&D efforts, increased its intellectual capital in 2020 with several additional patent acquisitions and in-house developed properties and software, along with key team additions. Guident has begun its B2B marketing program for its Remote Control and Monitoring Center and is seeking to consummate strategic alliances and partnerships in the last mile delivery, smart city and AV sectors. Such monitoring has recently been required by law in the State of Florida and is being reviewed in other jurisdictions. According to Allied Market Research[3], the global market for autonomous last mile delivery is projected to reach US$11.9 billion in 2021. Additionally, Guident has a acquired an exciting, new regenerative shock absorber technology, to help extend the range of electric vehicles. Guident has executed NDA's with two listed OEM's to test these new shocks for potential use in their electric vehicles and is currently fabricating prototypes for testing. Tekcapital owned 100% of Guident and approximately 96% of its U.S. subsidiary Guident Corporation as of 30 November 2020.
I actually agree with Gerry. If there is a support channel available for any product/service (not just DVRG) - this should be the first place that you should raise your issues/queries as they would be best placed to be able to help and pass on any feedback to the team.
Bypassing the dedicated support team and going straight to the CEO each time users have a query/issue does not work for the following reasons...
- Lab Skin have put in place a support team for a reason - use them as that's what they are getting paid for
- The CEO's time and energy should be focused on higher value activities and not responding to individual support cases - imagine if they have 1000 support queries - do you really want the CEO to be servicing/routing these 1000 support queries?
I would expect management to engage with the support team on a periodic basis to get a high level view of the common reported issues and take this into account when making strategic decisions on how STC app should be developed and improved. Need to remember that this is the first iteration and there are bound to be things that can be done better and improved.
Benr6789 - good job with providing that feedback and I definitely think it's worth providing that feedback to the support team if you haven't already done so.
I don't see any issue with Gerry's response and think it's a sensible and relevant response considering what I've mentioned above.
Want to WIN £500 worth of #Bitcoin? All you need to do is follow our Twitter page (@modeapp) to be in with a chance to win! Competition ends 19th May. T&Cs apply: https://loom.ly/uIMERKM
https://twitter.com/modeapp_/status/1392525520949194756?s=20
SAE, the global sustainable energy generation company and technology developer, wishes to announce that it has received correspondence in relation to the purported appointment of receivers over all of the shares of its major shareholder, SIMEC UK Energy Holdings Limited ("SUEH"), a GFG Alliance member, which SAE understands, owns approximately 43% of the issued share capital of SAE.
The GFG Alliance has informed SAE that it intends to challenge the validity of the appointment and is seeking appropriate advice. For the avoidance of doubt, SAE wishes to make clear that the above process relates to its major shareholder, SUEH and not to SAE itself. The GFG Alliance has also informed SAE that it wishes to make clear that SUEH is a holding company for the investment in SAE and the appointment of the receivers does not extend to the rest of the SIMEC group or other members of the GFG Alliance.
As a separate matter, SAE also notes that it will need to be determined from the receivers whether, assuming a valid appointment and enforcement of security pursuant to which that appointment is purported to have been exercised, a waiver from the Singapore Securities Industry Council to make a mandatory general offer for SAE under Rule 14 of the Singapore Code on Takeovers and Mergers arising from any such enforcement is required and, where required, has been obtained by the receivers.
SAE will make further announcements as required in relation to these matters and as further information becomes available. SAE also wishes to clarify again that, as announced on 7 April 2021, SAE is an independent company whose shares are admitted to trading on AIM and is not a member of the GFG Alliance.
Sounds like the board want to raise new funds?
Following the withdrawal of these resolutions at the AGM, the Directors do not currently have the authority to issue any new Ordinary Shares for cash or generally.
The Directors believe that having the authority to issue new Ordinary Shares is important for an investment company such as Tern as it:
? provides the Company with the flexibility to support its portfolio companies as required;
? gives the Company negotiating leverage when dealing with potential third-party investors in discussions about the portfolio companies;
? enables the Company to participate at short notice in potential fundraisings by its portfolio companies. If this is not possible, the Company could find its shareholdings in its portfolio companies are diluted and/or a lower valuation might be achieved in any such fundraise, which may then adversely impact upon the Company; and
? allows the Company to react quickly should an appropriate need for additional capital arise, particularly given the anticipated development pathways of many of the Company's portfolio companies and any appropriate potential investment opportunities that may arise.
The Resolutions would permit the Directors to issue up to 50 million new Ordinary Shares (representing approximately 15 per cent. of the Company's existing issued ordinary share capital) generally and for cash whilst disapplying the pre-emption rights of existing shareholders in relation to such an issue.
Should the Company seek to raise funds utilising the authorities that would be granted by the Resolutions through the issue of new Ordinary Shares it would use reasonable endeavours to utilise a platform such as PrimaryBid, as part of any offering, to allow retail shareholders the opportunity to participate in such fundraisings at the same price as other participants.
MOS have launched their platform in China now for a couple of months and the market over there is huge. Looking forward to seeing some news on how progress is going over there.
"We are pleased to announce that the Chinese language version of Streams will launch on 14 March. Streams China is aimed specifically at the Chinese market for companies that want to sell their products and services to a western audience. This will mark the first time we have launched an additional language version of the platform, and as indicated on 22 January we anticipate launching the Streams Data service in other key global markets during the year."
TEK currently own ~23% in Belluscura. With the new placing shares - this will get diluted. So actual holding on IPO will be worth around £7-£8 million once placing shares are taken into consideration.
From the recent Final Result RNS - Part 3
Guident owns or holds the exclusive licence to a group of patents that we believe can improve the safety of autonomous vehicles and land-based autonomous delivery devices once brought to market. Guident has significantly progressed it R&D efforts, increased its intellectual capital in 2020 with several additional patent acquisitions and in-house developed properties and software, along with key team additions. Guident has begun its B2B marketing program for its Remote Control and Monitoring Center and is seeking to consummate strategic alliances and partnerships in the last mile delivery, smart city and AV sectors. Such monitoring has recently been required by law in the State of Florida and is being reviewed in other jurisdictions. According to Allied Market Research[3], the global market for autonomous last mile delivery is projected to reach US$11.9 billion in 2021. Additionally, Guident has a acquired an exciting, new regenerative shock absorber technology, to help extend the range of electric vehicles. Guident has executed NDA's with two listed OEM's to test these new shocks for potential use in their electric vehicles and is currently fabricating prototypes for testing. Tekcapital owned 100% of Guident and approximately 96% of its U.S. subsidiary Guident Corporation as of 30 November 2020.
Belluscura has developed an improved portable oxygen concentrator to provide on-the-go supplemental O2, with user replaceable filter cartridges. When a patient's respiratory disease progresses, they now can upgrade the filter cartridge to provide more liters of O2 per minute, similar to upgrading memory on a laptop, rather than having to replace an expensive medical device. We believe the cost-savings will be beneficial to patients and insurance companies, and should help make respiratory healthcare more affordable which is core to Belluscura's mission. Belluscura filed for 510(K) clearance from the US FDA in December 2020 and received clearance in March 2021.
Belluscura have announced that they may plan to float on AIM or conduct an alternative financing, in the near-term, to finance and accelerate the manufacture and distribution of their portable oxygen concentrators. According to Global Market Insights, the medical portable O2 market is currently US$1.4bn[4] a year and growing by more thanUS$100m/year4. Belluscura has 18 patents filed or licensed to-date covering devices and systems for treating people suffering from acute respiratory distress caused by COPD or the Coronavirus pandemic. Tekcapital owned 17.8% of Belluscura as of 30 November 2020 and ~23% as of the date of this report.
From the recent Final Result RNS - Part 2
Salarius is a food tech business that owns a patented process to produce nanoparticle sized salt. These small crystals dissolve faster on the tongue, so you need to use less salt, whilst still having the same salty taste. Less salt means about 50% less sodium for most applications. Less sodium means a reduced likelihood of developing high blood pressure and heart disease, the world's leading cause of death. In addition to its focus on B2B sales of MicroSalt® to snack food companies, as proof of concept, Salarius has launched its own snack food brand called SaltMe!TM. Beginning in August 2020 they started shipping their first product, SaltMe! potato chips, to stores throughout the U.S. According to Future Market Insights, the low sodium ingredient market is estimated to reach US$1.76bn[1] by 2025. Tekcapital owns 97.15% of Salarius and 87.1% of its U.S. subsidiary Microsalt Inc. as of the date of this report.
Lucyd has built a new, online eyeglass business that combines technology with traditional eyewear. Recently they launched Lucyd LyteTM, their most advanced and compelling Bluetooth® eyewear. This product combines proper prescription, designer glasses with Bluetooth technology that you can use to answer your phone, listen to music, and talk with Siri® or Alexa®. The product has initially been very well received. Lucyd is focused on expanding its sales online and leveraging retail distribution after the pandemic subsides, through existing specialty and large format stores in late 2021. Lucyd has developed and filed 24 U.S. utility and design patents covering its products. According to Statista[2], the current U.S. online market for eyewear is $3.8b per year. Tekcapital owned 100% of Lucyd and 90% of its U.S. subsidiary Innovative Eyewear Inc as of 30 November 2020.
From the recent Final Result RNS - Part 1
Chairman's statement
Tekcapital brings new scientific innovations from lab to market to enhance safety and health and improve the quality of life of the customers we serve. Achieving our mission has never been more important than right now, as the COVID 19 pandemic has resulted in significant and unprecedented global health and financial distress.
In 2020, despite these events, all of our active portfolio companies made significant progress and the value of our portfolio holdings increased by 50%. As a result, for the year, our net assets increased by approximately 45% to US$32.7m, a record level for our Company. Total revenues increased 28% to US$9.9m while our after-tax profit increased by 39% to US$7.7m.
Key portfolio companies
Using our proprietary global university network, we provide services to universities and companies to help them commercialize their innovations. Additionally, over the past four years, using these services, we have built a valuable group of portfolio companies to commercialize select intellectual properties we or our portfolio companies have uncovered. We believe that when you couple commercialization ready, compelling university IP with visionary management, vibrant companies will likely emerge, net assets are likely to grow, returns on invested capital will outperform the sector and exits, if they occur, will occur faster. When we realise exits through trade sales or IPO's, the Group's goal is to distribute a portion of the proceeds as a special dividend to our shareholders.
Our current portfolio companies were all started by Tekcapital from a clean sheet of paper. Whilst few in number, they are diverse and span multiple sectors including food tech, autonomous vehicles, smart eyewear and respiratory medical devices. In our view, all of our portfolio companies have compelling intellectual properties, capable and inspired management and address US$B+, fast growing markets. The entire team at Tekcapital is committed to helping these companies grow to achieve their full potential and value, which we view as significant.
https://www.londonstockexchange.com/news-article/market-news/intention-to-float-aim/14967248
Belluscura's first product, the X-PLO2RTM, is a lightweight FDA cleared portable oxygen concentrator ("POC") designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25lbs) and the Directors believe it is the world's first modular portable oxygen concentrator and that it will generate more oxygen by weight than any other FDA cleared POC in its class. The X-PLO2R can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week to help improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and respiratory distress caused by COVID-19. The X-PLO2R will be launched shortly and additional products within the range will be launched within the next 12 months.
Belluscura either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.
The Company is seeking to raise £15 million via a conditional placing of shares ("Placing") to support the commercial roll-out of the X-PLO2R and to progress Belluscura's oxygen enrichment product portfolio. Following completion of the Placing and Admission to AIM, Belluscura is expected to be valued in the region of £50-55 million.
SPARK Advisory Partners is acting as Nominated Adviser, and Dowgate Capital is sole Broker and Bookrunner in relation to the proposed Placing.
Key highlights
· £15 million to be raised (before expenses) through a conditional placing with institutional investors at between 42-48 pence per new Ordinary Share
· The net proceeds of the Placing will be used by the Company:
- To widen staffing resources within Engineering & Quality, Marketing, Sales & Customer Service, Compliance & Finance and appointing a key Manufacturing & Regulatory Executive
- Marketing of the product ranges, including building the brand, improving the website functionality and SEO and social media presence
- Funding towards the FDA Medical Device Compliance, IT & Data Compliance and CE Mark Clearance
- Research & Development into new products and increasing testing capabilities
- Funding for the overheads of the firm, such as running the offices, and;
- Initial working capital funding
· Expected market capitalisation on Admission in the region of of £50-55 million
· Admission and commencement of dealings on AIM expected to take place in late May
The Company will publish an Admission Document which will be available in due course on the Company's website: https://www.belluscura.com
TEK currently own ~23% in Belluscura. With the new placing shares - this will get diluted. So actual holding will be worth around £7-£8 million once placing shares are taken into consideration.
Refer to the Final Results RNS
https://www.lse.co.uk/rns/TEK/final-results-hs0qyfxmkhy3mvl.html
· In April 2021, the Company converted its warrants and options for shares of Belluscura plc, bringing total shares held to 17.1 million (~23%).
Expected market capitalisation on Admission in the region of of £50-55 million.
TEK own ~23% in Belluscura => £11.5-£12.65 million.
Current market cap of TEK ~£17m
The below is from the RNS dated 20th Oct 2020 where Vela announced they had invested £1.25 million cash into the Arcadia project which will be concluding at the end of this month. Assuming that the results are good, which SGS has anticipated by taking a big chunk of the project investment in Vela shares which were issued at 0.10p - we should see Vela rerate significantly from the current price.
· Vela (AIM: VELA) has acquired an economic interest in a late-stage Phase II therapeutic project to develop a potential coronavirus treatment for diabetics
· Strategic partners in the project include, amongst others, a major global pharmaceutical company, UKRI - UK Research and Innovation, Professor Sir Christopher Evans and Mubadala - the UAE sovereign wealth fund
· Following completion of a £10.3 million investment in August 2020, the project is now fully funded with results of current Phase II trial expected in Q2 2021
· Consideration of £2.35 million satisfied by Vela raising £1.25 million via a placing of new ordinary shares at 0.065 pence per share and the issuance of 1,100,000,000 locked-in consideration shares at a price of 0.1 pence per share
We have 280 MS of hash rate for ZEC mining and we do convert the mined ZEC into BTC on a daily basis. The daily ZEC mining ?revenue is around $37,400 excluding cost of mining. If you take into account the cost of power then I would assume we can get 1 bitcoin every 2 days just from our ZEC mining.
If ZEC can get back to it's ATH of $5272 then this will mean a major source of revenue for Argo. Of course the difficulty will rise but that price rise would be around 18x from $290.